Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

H. Ratner, Paul; P. Andrews, Charles; C. Hampel, Frank; G. Martin, Bruce; Mohar, Dale; Bourrelly, Denis; Danaietash, Parisa; Mangialaio, Sara; Dingemanse, Jasper; Hmissi, Abdel; van Bavel, J.

doi:10.1186/s13223-017-0183-z

Public

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Published in Allergy Asthma and Clinical Immunology • Apr 4, 2017

Authors:

Paul H. Ratner

Charles P. Andrews

Frank C. Hampel

Abstract

BACKGROUND: Antagonism of chemoattractant receptor-homologous molecule on T-helper type-2 cells (CRTH2), a G-protein coupled receptor for prostaglandin D2, could be beneficial for treating allergic disorders. We present findings on the efficacy and safety/tolerability of a CRTH2 antagonist (setipipr...

Subject

Placebo

Medicine

Tolerability

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!